© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
May 15, 2022
The AUA partnered with ASTRO on the guideline and it was endorsed by the SUO.
The findings came from a post-hoc analysis of the phase 3 ARCHES trial.
May 14, 2022
“Relugolix, an oral nonpeptide GnRH receptor antagonist, was generally well tolerated in the phase 3 HERO study,” wrote Bryan Mehlhaff, MD, and coauthors.
A regimen combining the PARP inhibitor and the androgen receptor pathway inhibitor plus prednisone showed promise in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.
No grade 3 TEAEs were reported in more than 1 patient at a time, and investigators deemed these grade 3 TEAEs to be unrelated to darolutamide treatment.
“I had long thought that vitamin D deficiency could be a risk factor for prostate cancer,” says Adam B. Murphy, MD, MBA, MSCI.
Compared with baseline conventional imaging, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging in men with prostate cancer recurrence, according to the latest data from the phase 3 SPOTLIGHT trial.
October 04, 2021
In a recent study presented at the 2021 AUA Annual Meeting, Scarlett Gomez, MPH, PhD, and co-authors investigated the determinants of selecting active surveillance/watchful waiting as a treatment path for patients with localized, low-risk prostate cancer.
October 01, 2021
In a study presented at the 2021 AUA annual meeting, Behfar Ehdaie, MD, MPH, and colleagues assessed the efficacy of focal therapy in treating patients with grade group 2 or 3 prostate cancers.
September 30, 2021
Dharam Kaushik, MD, and a team of investigators are the first to examine the benefits of perioperative yoga in patients diagnosed with localized prostate cancer.